Vaccine Potentials of an Intrinsically Unstructured Fragment Derived from the Blood Stage-Associated Plasmodium falciparum Protein PFF0165c

Author:

Olugbile S.1,Kulangara C.2,Bang G.3,Bertholet S.4,Suzarte E.5,Villard V.5,Frank G.5,Audran R.1,Razaname A.5,Nebie I.6,Awobusuyi O.7,Spertini F.1,Kajava A. V.8,Felger I.2,Druilhe P.3,Corradin G.5

Affiliation:

1. Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland

2. Swiss Tropical Institute, Basel, Switzerland

3. Pasteur Institute, Paris, France

4. Infectious Disease Research Institute, Seattle, Washington

5. Biochemistry Department, University of Lausanne, Epalinges, Switzerland

6. Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso

7. Lagos State University Teaching Hospital, Lagos, Nigeria

8. CRBM, CNRS, University of Montpellier, Montpellier, France

Abstract

ABSTRACT We have identified new malaria vaccine candidates through the combination of bioinformatics prediction of stable protein domains in the Plasmodium falciparum genome, chemical synthesis of polypeptides, in vitro biological functional assays, and association of an antigen-specific antibody response with protection against clinical malaria. Within the predicted open reading frame of P. falciparum hypothetical protein PFF0165c, several segments with low hydrophobic amino acid content, which are likely to be intrinsically unstructured, were identified. The synthetic peptide corresponding to one such segment (P27A) was well recognized by sera and peripheral blood mononuclear cells of adults living in different regions where malaria is endemic. High antibody titers were induced in different strains of mice and in rabbits immunized with the polypeptide formulated with different adjuvants. These antibodies recognized native epitopes in P. falciparum -infected erythrocytes, formed distinct bands in Western blots, and were inhibitory in an in vitro antibody-dependent cellular inhibition parasite-growth assay. The immunological properties of P27A, together with its low polymorphism and association with clinical protection from malaria in humans, warrant its further development as a malaria vaccine candidate.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Reference39 articles.

1. Alderson, M. R., P. McGowan, J. R. Baldridge, and P. Probst. 2006. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res.12:313-319.

2. Colloids Surf. B

3. Solid phase synthesis; a practical approach. 1989

4. Audran, R., M. Cachat, F. Lurati, S. Soe, O. Leroy, G. Corradin, P. Druilhe, and F. Spertini. 2005. Phase 1 malaria vaccine trial with a long synthetic peptide derived from merozoite surface protein 3. Infect. Immun.3:8017-8026.

5. Baldridge, J. R., P. McGowan, J. T. Evans, C. Cluff, S. Mossman, D. Johnson, and D. Persing. 2004. Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and immunotherapeutic agents. Expert Opin. Biol. Ther.4:1129-1138.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3